Amgen
- Country
- Ownership
- -
- Employees
- 26.7K
- Market Cap
- -
- Introduction
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
QureBio Secures $14 Million Series C1 Funding to Advance Bispecific Antibody Pipeline
QureBio completed a Series C1 financing round raising nearly CNY 100 million (approximately USD 14 million) led by Efung Capital to accelerate clinical trials of its novel antibody therapeutics.
Protein Therapeutics Market Surges to $400 Billion as 20 New Drugs Gain Approval in 2023
The global protein therapeutics market reached an estimated $400 billion in value, driven by increasing pharmaceutical company investment in advanced protein-based drug development strategies.
Racial Disparities Persist in Triple-Negative Breast Cancer Trials Despite Treatment Advances
• Black women face disproportionate burden of triple-negative breast cancer with higher incidence and mortality rates, yet comprise only 6.5% of clinical trial participants versus 14.4% US population representation. • Recent advances in small cell lung cancer treatment include promising DLL3-targeting therapy tarlatamab-dlle, offering new hope for patients with disease progression after platinum-based chemotherapy. • FDA's approval of fam-trastuzumab deruxtecan-nxki marks significant progress in site-agnostic cancer therapy, demonstrating efficacy across multiple HER2-positive solid tumors.
BridgeBio's Attruby Approved for ATTR-CM, Cassava's Simufilam Fails in Alzheimer's Trial
BridgeBio Pharma's Attruby (acoramidis) receives FDA approval for transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization.
Merck Launches First Phase 3 Program for Oral PCSK9 Inhibitor MK-0616 to Treat High Cholesterol
Merck has initiated the first Phase 3 clinical program for an oral PCSK9 inhibitor, MK-0616, marking a potential breakthrough in cholesterol treatment with a once-daily pill format.